West Virginia residents are facing a difficult reality as the state ends its subsidy program for GLP-1 weight loss drugs, leaving many unable to afford the medication that has been life-changing for some. The abrupt termination of this program has left residents, like Hilaria Swisher, scrambling for alternatives and coping with the emotional and physical toll of losing access to the treatment.
The Impact of Rising Costs on Weight Loss Efforts
GLP-1 drugs, which have gained popularity for their effectiveness in helping people lose weight, have been life-altering for individuals like Hilaria Swisher. After struggling with weight issues for years, Swisher began using GLP-1 injections in January and lost over 27% of her body weight. However, the cost of the drugs is out of reach for many, especially in a state like West Virginia, where the obesity rate is the highest in the nation.
In 2020, West Virginia launched a pilot program to subsidize these drugs for public employees, offering a lifeline to teachers, law enforcement officers, and city workers. Swisher, who qualified for the program through her husband’s employment, was paying just $25 a month for her medication. But in March 2024, the state insurance agency abruptly ended the program, citing high costs and supply shortages.
Now, with the program gone, many are left facing monthly costs of over $1,000 for the drugs. Lori Osborne, another program beneficiary who lost 70 pounds, says the sudden end of the subsidy feels like “false hope.” She is now forced to explore cheaper, non-FDA-approved alternatives or risk regaining the weight she worked so hard to lose.
Experts argue that ending the program is a costly mistake, as the long-term health consequences of untreated obesity will ultimately fall on the state’s healthcare system. For now, residents like Swisher are left to ration their medication, uncertain of what the future holds.
